Evidence map›Paper›PMID 33809632›Full record

ReviewInternational journal of molecular sciences2021

Extracellular Vesicles from Mesenchymal Stromal Cells for the Treatment of Inflammation-Related Conditions.

Sean T Ryan, Elham Hosseini-Beheshti, Dinara Afrose, Xianting Ding, Binbin Xia, Georges E Grau, Christopher B Little, Lana McClements, Jiao Jiao Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Basic Guide for Approaching Drug Delivery with Extracellular Vesicles.International journal of molecular sciences · 2024
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.International journal of molecular sciences · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sean T RyanKolling Institute, Faculty of Medicine and Health, University of Sydney, St. Leonards, NSW 2065, Australia.
Elham Hosseini-BeheshtiFaculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia.
Dinara AfroseFaculty of Science, School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Xianting DingInstitute for Personalized Medicine, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China.
Binbin XiaFaculty of Engineering and IT, School of Biomedical Engineering, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Georges E GrauFaculty of Medicine and Health, School of Medical Sciences, University of Sydney, Camperdown, NSW 2006, Australia.
Christopher B LittleKolling Institute, Faculty of Medicine and Health, University of Sydney, St. Leonards, NSW 2065, Australia.ORCID 0000-0002-0353-7634
Lana McClementsFaculty of Science, School of Life Sciences, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0002-4911-1014
Jiao Jiao LiKolling Institute, Faculty of Medicine and Health, University of Sydney, St. Leonards, NSW 2065, Australia.ORCID 0000-0002-3584-6765
The University of Sydney · AUUniversity of Technology Sydney · AUShanghai Jiao Tong University · CN

Funding

National Health and Medical Research Council GNT1120249New South Wales Workers' Compensation Dust Disease Board N/A
6 · The paper itself

Abstract

Over the past two decades, mesenchymal stromal cells (MSCs) have demonstrated great potential in the treatment of inflammation-related conditions. Numerous early stage clinical trials have suggested that this treatment strategy has potential to lead to significant improvements in clinical outcomes. While promising, there remain substantial regulatory hurdles, safety concerns, and logistical issues that need to be addressed before cell-based treatments can have widespread clinical impact. These drawbacks, along with research aimed at elucidating the mechanisms by which MSCs exert their therapeutic effects, have inspired the development of extracellular vesicles (EVs) as anti-inflammatory therapeutic agents. The use of MSC-derived EVs for treating inflammation-related conditions has shown therapeutic potential in both in vitro and small animal studies. This review will explore the current research landscape pertaining to the use of MSC-derived EVs as anti-inflammatory and pro-regenerative agents in a range of inflammation-related conditions: osteoarthritis, rheumatoid arthritis, Alzheimer's disease, cardiovascular disease, and preeclampsia. Along with this, the mechanisms by which MSC-derived EVs exert their beneficial effects on the damaged or degenerative tissues will be reviewed, giving insight into their therapeutic potential. Challenges and future perspectives on the use of MSC-derived EVs for the treatment of inflammation-related conditions will be discussed.

Indexed as

AnimalsExtracellular VesiclesHumansInflammationMesenchymal Stem CellsModels, BiologicalAlzheimer’s diseasecardiovascular diseaseextracellular vesiclesinflammationmesenchymal stromal cellsosteoarthritispreeclampsiaregenerationrheumatoid arthritis

Identifiers

PMID33809632
PMCPMC8002312
OpenAlexW3137136283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.